Showing results (171-180 of 233) with videos related to

Sort By:
Pageof 24
American Journal of Hematology|January 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myelomaXuehan Mao, Wenqiang Yan, David Mery, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Stem Cells (Dayton, Ohio)|July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li, Wen Ling, Angela Pennisi, et al.
Haematologica|March 24, 2018
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myelomaFaith E Davies, Adam Rosenthal, Leo Rasche, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in MyelomaJames E McDonald, Marcus M Kessler, Michael W Gardner, et al.
Haematologica|August 30, 2023
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myelomaLindsay Hammons, Aniko Szabo, Abhishek Janardan, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Pageof 24